BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21142269)

  • 1. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.
    Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Laine K; Olkkola KT
    Clin Drug Investig; 2011; 31(3):143-53. PubMed ID: 21142269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
    Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
    Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Kummer O; Hammann F; Moser C; Schaller O; Drewe J; Krähenbühl S
    Eur J Clin Pharmacol; 2011 Jan; 67(1):63-71. PubMed ID: 20857093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
    Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
    J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
    Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
    J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
    Saari TI; Grönlund J; Hagelberg NM; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2010 Apr; 66(4):387-97. PubMed ID: 20076952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.
    Lemberg KK; Heiskanen TE; Neuvonen M; Kontinen VK; Neuvonen PJ; Dahl ML; Kalso EA
    Scand J Pain; 2010 Jan; 1(1):24-33. PubMed ID: 29913934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.
    Saarikoski T; Saari TI; Hagelberg NM; Backman JT; Neuvonen PJ; Scheinin M; Olkkola KT; Laine K
    Eur J Clin Pharmacol; 2015 Mar; 71(3):321-7. PubMed ID: 25560051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
    Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
    Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4.
    Grönlund J; Saari TI; Hagelberg N; Neuvonen PJ; Olkkola KT; Laine K
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1063-7. PubMed ID: 21173180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
    Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
    Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations of urinary oxycodone and metabolite distributions in pain patients.
    Elder NM; Atayee RS; Best BM; Ma JD
    J Anal Toxicol; 2014 Apr; 38(3):129-34. PubMed ID: 24523296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.